Pearce IP BioBlast™: w/e 01 January 2021

by | Jan 2, 2021

27 Dec 20 | CN | Innovent announced China’s NMPA has approved Byvasda® (biosimilar bevacizumab) for the additional indication of adult recurrent glioblastoma.


30 Dec 20 | Alvotech announced it has broken ground on the extension to its high-tech centre in Reykjavik. The extension will house biosimilar development, drug refills, offices and warehouses, and is expected to be completed by the end of 2022.
Print Page Mail Article

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News